- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.09. | TRANSTHERA-B (02617): INTERIM REPORT 2026 | 1 | HKEx | ||
| 21.09. | TRANSTHERA-B Tinngotinib Included in CSCO Guidelines for Diagnosis and Treatment of Biliary Tract Malignancies | 9 | AASTOCKS | ||
| 18.09. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF TINENGOTINIB IN COMBINATION WITH NOVEL HORMONAL THERAPY ... | - | HKEx | ||
| 18.09. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT INCLUSION OF YOCHANRA (TINENGOTINIB) IN THE CSCO GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF BILIARY TRACT ... | 1 | HKEx | ||
| TRANSTHERA SCIENCES Aktie jetzt für 0€ handeln | |||||
| 26.08. | TRANSTHERA-B (02617): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026 | - | HKEx | ||
| 14.08. | TRANSTHERA-B (02617): DATE OF BOARD MEETING | - | HKEx | ||
| 07.08. | TransThera's resistant biliary cancer drug cleared in China | - | pharmaphorum | ||
| 06.08. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT MARKETING APPROVAL FOR YOCHANRA (TINENGOTINIB TABLETS) GRANTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION | - | HKEx | ||
| 24.07. | TRANSTHERA-B (02617): GRANT OF SHARE AWARDS AND SHARE OPTIONS UNDER THE H SHARE AWARD SCHEME | 1 | HKEx | ||
| 17.07. | TRANSTHERA-B (02617): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 10.07. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT APPROVAL FOR CONDUCTING CHINA PHASE II CLINICAL TRIAL OF TT-00973 TABLETS IN COMBINATION WITH FIRMONERTINIB ... | 2 | HKEx | ||
| 06.07. | TransThera Completes Late-Stage Trial Enrollment For Bile Duct Cancer Drug | 3 | Benzinga.com | ||
| 01.07. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT ENROLLMENT COMPLETED IN THE GLOBAL MULTICENTER REGISTRATIONAL PHASE III CLINICAL TRIAL OF TINENGOTINIB MONOTHERAPY ... | 2 | HKEx | ||
| 01.07. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT APPROVAL GRANTED FOR PHASE II CLINICAL TRIAL IN CHINA OF TT-01488 TABLETS IN COMBINATION WITH ANTI-CD20 MONOCLONAL ... | - | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE STRATEGY COMMITTEE OF THE BOARD OF DIRECTORS | 2 | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE REMUNERATION AND APPRAISAL COMMITTEE OF THE BOARD OF DIRECTORS | - | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | - | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): ARTICLES OF ASSOCIATION | 2 | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,405 | +5,80 % | EQS-News: CPT GmbH: Warren Wise entschlüsselt Qiagens DNA | EQS-News: CPT GmbH
/ Schlagwort(e): Research Update/Jahresbericht
Warren Wise entschlüsselt Qiagens DNA
25.09.2026 / 18:15 CET/CEST
Für den Inhalt der Mitteilung ist... ► Artikel lesen | |
| CG ONCOLOGY | 67,38 | -1,42 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 39,640 | +0,18 % | Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days | ||
| TARSUS PHARMACEUTICALS | 73,00 | -3,26 % | Tarsus Pharmaceuticals, Inc: Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting | ||
| PRAXIS PRECISION MEDICINES | 295,78 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| VERA THERAPEUTICS | 30,420 | -1,84 % | Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 | BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,755 | -0,92 % | Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft | DJ Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft
Von Elias Schisgall
DOW JONES--Astrazeneca investiert im Rahmen einer erweiterten Partnerschaft 2 Milliarden... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,225 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 10,500 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk | In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized... ► Artikel lesen | |
| MBX BIOSCIENCES | 58,51 | 0,00 % | Guggenheim raises MBX Biosciences price target to $150 on obesity drug potential | ||
| EDGEWISE THERAPEUTICS | 41,400 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 27,790 | -1,03 % | Stifel reiterates Amylyx stock rating on avexitide confidence | ||
| KYMERA THERAPEUTICS | 107,37 | -2,44 % | B.Riley reiterates Kymera Therapeutics stock rating on new trial data | ||
| ADARX PHARMACEUTICALS | 18,250 | -6,60 % | HBM Healthcare Investments AG: HBM Healthcare Investments erhöht Beteiligung an der Portfoliogesellschaft ADARx Pharmaceuticals im Rahmen des Börsengangs | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
HBM Healthcare Investments erhöht Beteiligung an der Portfoliogesellschaft ADARx Pharmaceuticals im Rahmen des Börsengangs... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,125 | -0,12 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen |
Das Unternehmen TRANSTHERA SCIENCES NANJING INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,170 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSTHERA SCIENCES NANJING INC finden Sie auf Wallstreet Online.